BioNTech SE (BNTX) Current Deferred Revenue (2018 - 2025)

BioNTech SE has reported Current Deferred Revenue for 8 years, with the latest figure at $981.2 million in Q4 2025.

• Quarterly Current Deferred Revenue rose 92.13% year-over-year to $981.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $981.2 million (up 92.13% YoY) and the FY2025 annual result came in at $952.3 million, up 86.48% from the prior year.
• Current Deferred Revenue improved to $981.2 million in Q4 2025 per BNTX's latest filing, from $930.7 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $1.1 billion in Q2 2025 and troughed at $48.9 million in Q1 2023.
• A 5-year average of $495.0 million and a median of $412.9 million in 2024 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue plunged 77.29% in 2023, then jumped 741.67% in 2024.
• Over 5 years, Current Deferred Revenue stood at $212.9 million in 2021, then plunged by 39.86% to $128.0 million in 2022, then soared by 531.74% to $808.9 million in 2023, then tumbled by 36.87% to $510.7 million in 2024, then soared by 92.13% to $981.2 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $981.2 million, $930.7 million, and $1.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.